p62 gene therapy

p62 gene therapy is a preclinical-stage gene therapy program developed by STC Life. The therapy is designed to target or modulate the p62 gene (Sequestosome 1 or SQSTM1), a multifunctional protein that plays a critical role in autophagy, the ubiquitin-proteasome system, and various cell signaling pathways. By regulating p62, the therapy aims to treat a broad spectrum of conditions, including various types of cancer, neurodegenerative diseases such as Alzheimer's and Parkinson's, and metabolic disorders. The specific mechanism—whether it involves gene addition, silencing, or editing—has not been publicly detailed by the developer.

Other names

SQSTM1 gene therapySQSTM-1 gene therapySQSTM 1 gene therapy